看多
NOVA gets FDA approval
Great news this morning for NOVA that should help push its momentum towards first resistance level in the next days and could definitely breakthrough if volume continues up from this news.
The U.S. Food and Drug Administration has approved Nova Mentis Life Science Corp.'s proprietary psilocybin drug orphan drug application to treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder (ASD).
This is a small biotech, so do your DD and analysis.
The U.S. Food and Drug Administration has approved Nova Mentis Life Science Corp.'s proprietary psilocybin drug orphan drug application to treat patients with fragile X syndrome (FXS), the most common inherited cause of autism spectrum disorder (ASD).
This is a small biotech, so do your DD and analysis.
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。
免責聲明
這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。